Olivier Véran requests a revision of the recipe rules in France

Health Minister Olivier Véran on Saturday asked the University of Public Health to review the “reductive prescription rules” for hydroxychloroquine and chloroquine, following the publication of a study that pointed out its inefficiency and its risks for Covid-19 patients.

Olivier Véran responds to the extensive study published on Friday, May 22, pointing to the inefficiency of hydroxychloroquine and chloroquine on patients admitted to Covid-19. On Saturday, May 23, the French Minister of Health asked the University of Public Health (HCSP) to propose “within 48 hours a review of the reductive prescription rules” of these treatments.

“Following the publication in The Lancet of a study warning of the ineffectiveness and risks of certain treatments for Covid-19 including hydroxychloroquine, I asked HCSP to analyze it and offer me a review of the excess prescription rules within 48 hours,” the minister said in a tweet .

A treatment that crystallizes the debates

In addition to clinical trials, France has already restricted the use of hydroxychloroquine (HCQ) only in hospitals and only for serious cases on doctors’ collegial decisions.

This molecule, derived from the antimalarial chloroquine, has known an unprecedented notoriety since the end of February since Professor Didier Raoult, University University Institute (IHU) in Marseille, relayed a small, somewhat detailed Chinese study and claimed that chloroquine phosphate showed signs of efficacy in patients with SARS-CoV2.

Chloroquine ineffective: “we have to separate opinions and scientific facts”

Two studies, one Chinese and one French, published last week, however, found that HCQ did not reduce the risk of admission to intensive care or death in patients with pneumonia due to Covid-19.

And another study, with data on a total of 96,000 patients, published Friday in The Lancet, to which Olivier Véran claims in his tweet, concluded that neither chloroquine nor HCQ are effective against Covid-19 in hospitalized patients. According to this study, these molecules even increase the risk of death and arrhythmia

With AFP